Chinese Japanese Germany Korea


Description Overview and History Application Mode of action Adverse reactions Dose titration Warning Precaution References
brivaracetam structure
Chemical Name:
Briviact;UCB-34714;brivaracetam;API-Anti Epilepsy;2(S)-[2-Oxo-4(R)-propylpyrrolidin-1-yl]butyramide;(S)-2-((R)-2-oxo-4-propylpyrrolidin-1-yl)butanaMide;(2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide;1-PyrrolidineacetaMide, α-ethyl-2-oxo-4-propyl-, (αS,4R)-;(alphaS,4R)-alpha-Ethyl-2-oxo-4-propyl-1-pyrrolidineacetamide
Molecular Formula:
Formula Weight:
MOL File:

brivaracetam Properties

Melting point:
D25 -60.57° (c = 1 in methanol)
Boiling point:
409.3±28.0 °C(Predicted)

brivaracetam price More Price(4)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Cayman Chemical 23873 Brivaracetam ≥98% 357336-20-0 10mg $99 2018-11-19 Buy
Cayman Chemical 23873 Brivaracetam ≥98% 357336-20-0 25mg $149 2018-11-19 Buy
Cayman Chemical 23873 Brivaracetam ≥98% 357336-20-0 50mg $272 2018-11-19 Buy
Cayman Chemical 23873 Brivaracetam ≥98% 357336-20-0 100mg $446 2019-12-02 Buy

brivaracetam Chemical Properties,Uses,Production


Brivaracetam, a chemical analog of Levetiracetam, is a racetam derivative with anticonvulsant effect. It is used for the treatment of partial-onset seizures with or without secondary generalisation, in combination with other antiepileptic drugs. The exact mechanism of brivaracetam's anti-epileptogenic activity is unknown. What is known is thatbrivaracetam binds SV2A with high affinity. SV2A is known to play a role in epileptogenesis through modulation of synaptic GABA release. It is thought that brivaracetam exerts its anti-epileptogenic effects through its binding to SV2A. Brivaracetam can also inhibit Na+ channels which may also contribute to its anti-epileptogenic action.

Overview and History

Brivaracetam is an orally bioavailable levetiracetam derivative, with anticonvulsant activity. It can be used in the treatment of partial-onset seizures[1-3]. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam. It is available under the brand name Briviact made by UCB. It was approved by the federal drug administration of USA[FDA] on Feb 19th 2016[1-3].


Brivaracetam is indicated for the treatment of partial-onset seizures in patients 4 years of age and older[4,5]. It provides a new monotherapy treatment option for epilepsy patients 16 years of age and older who suffering partial-onset[focal] seizures, which can be initiated at a therapeutic dose at day one[5].

Mode of action

The accurate mode of action of brivaracetam remains unclear. It is known that Brivaracetam can strongly bind to SV2A[6-8], which is known to play a role in epileptogenesis through modulation of synaptic GABA release. It is thought that brivaracetam exerts its anti-epileptogenic effects through its binding to SV2A[6-8]. It may access the luminal side of recycling synaptic vesicles during vesicular endocytosis, which may reduce excitatory neurotransmitter release and enhance synaptic depression during trains of high-frequency activity, such as is believed to occur during epileptic activity. Brivaracetam is also known to inhibit Na+ channels which may also contribute to its anti-epileptogenic action[9].

Adverse reactions

The most frequently reported adverse reactions associated with brivaracetam treatment are somnolence and dizziness (both somnolence and fatigue are reported with a higher incidence with increasing dose). Preliminary metaanalytic data comparing the incidence of behavioural problems in brivaracetam and levetiracetam trials (used as adjunctive therapy in adults with uncontrolled partial- onset epilepsy) showed that the incidence of non- psychotic behavioural treatment emergent adverse effects was considerably lower with brivaracetam treatment (6.8%) compared with levetiracetam (10.9%), whereas the incidences in placebo arms were similar (4.2 and 4.8%, respectively). The placebo- adjusted incidence rates were 2.6% for brivaracetam and 6.8% for levetiracetam, resulting in a brivaracetam/levetiracetam Odds Ratio of 0.68. Brivaracetam has a low interaction potential, although it is not recommended for use with concomitant levetiracetam.

Dose titration

Brivaracetam is known under the proprietary name of Briviact® (UCB Pharma, Slough) in the UK and USA. Brivaracetam is available in different pharmaceutical forms (10-25-50-75-100 mg film- coated tablets and 10 mg/ mL oral solution). Brivaracetam is initially prescribed at the dose of 50–100 mg daily, divided into two doses. Based on individual patient response and tolerability, the dose may be adjusted within the dose range of 50– 200 mg daily. Brivaracetam is recommended as an adjunctive AED treatment for partial- onset seizures with or without secondary generalization. Brivaracetam exhibits greater antiepileptic properties than levetiracetam in animal models, but with a somewhat smaller (although still high) therapeutic range. Moreover, brivaracetam requires no up- titration to reach therapeutic doses and there is no recommendation for specific monitoring. Exposure to brivaracetam is increased in patients with chronic liver disease. A starting dose of 50 mg daily should be considered and a maximum daily dose of 150 mg administered, divided into two doses, is recommended for all stages of hepatic impairment. If patients missed one dose or more, it is recommended that they take a single dose as soon as they remember and take the following dose at the usual morning or evening time, in order to avoid the brivaracetam plasma concentration falling below the efficacy level and prevent breakthrough seizures from occurring. If brivaracetam has to be discontinued, it is recommended to withdraw it gradually by 50 mg daily on a weekly basis. After 1 week of treatment at 50 mg daily, a final week of treatment at the dose of 20 mg daily is recommended.


It is possible that BRIVIACT can cause the following severe adverse effects, special attention should pay immediately once those following cases occur[4, 10, 11].
Suicidal Behavior and Ideation: Antiepileptic drugs can increase the risk of suicidal behavior and ideation. Monitor patients taking BRIVIACT for the emergence or worsening of depression; unusual changes in mood or behavior; or suicidal thoughts, behavior, or self-harm. Advise patients, their caregivers, and/or families to be alert for these behavioral changes and report them immediately to a healthcare provider[4].
Psychiatric Adverse Reactions: BRIVIACT can also cause psychiatric adverse reactions, including non-psychotic and psychotic symptoms. These events were reported in approximately 13% of patients taking at least 50 mg per day of BRIVIACT compared to 8% of patients taking placebo. A total of 1.7% of adult patients taking BRIVIACT discontinued treatment due to psychiatric reactions compared to 1.3% of patients taking placebo. Advise patients to report these symptoms immediately to a healthcare provider[10].
Hypersensitivity: BRIVIACT can cause hypersensitivity reactions such as bronchospasm and angioedema. The patients should discontinue BRIVIACT if a he/she develops a hypersensitivity reaction after treatment. BRIVIACT should not be applied in patients with a prior hypersensitivity reaction to brivaracetam or any of the inactive ingredients[10].
Neurological Adverse Reactions: BRIVIACT causes somnolence, fatigue, dizziness, and disturbance in coordination. Somnolence and fatigue-related adverse reactions were reported in 25% of patients taking at least 50 mg per day of BRIVIACT compared to 14% of patients taking placebo. Dizziness and disturbance in gait and coordination were reported in 16% of patients taking at least 50 mg per day of BRIVIACT compared to 10% of patients taking placebo. The risk is greatest early in treatment but can occur at any time. Monitor patients for these signs and symptoms and advise them not to drive or operate machinery until they have gained sufficient experience on BRIVIACT[4].
Withdrawal of Antiepileptic Drugs: BRIVIACT should generally be withdrawn gradually because of the risk of increased seizure frequency and status epilepticus[4].


You should not use brivaracetam if you are allergic to it[4, 11, 12].
Brivaracetam may become habit-forming for people administrate. Therefore, it is of risk to share brivaracetam with another person, especially avoid sharing with someone with a history of drug abuse or addiction. You should keep the medication in a place where others cannot get to it. Selling or giving away this medicine is against the law.
Before administrate the brivaracetam, tell your doctor if you have ever had one or several of the following symptom for your own safety: Depression or a mood disorder; Suicidal thoughts or actions; liver disease; or alcoholism or drug addiction.
Follow your doctor's instructions about taking seizure medication if you are pregnant. Seizure control is very important during pregnancy, and having a seizure could harm both mother and baby. Do not start or stop taking this medicine without your doctor's advice, and tell your doctor right away if you become pregnant. If you are pregnant, your name may be listed on a pregnancy registry. This is to track the outcome of the pregnancy and to evaluate any effects of brivaracetam on the baby.
It is not known whether brivaracetam passes into breast milk or if it could harm a nursing baby. Tell your doctor if you are breast-feeding a baby.
Brivaracetam is not approved for use by anyone younger than 16 years old[4].
Patients of hepatic impairment should subject to dose adjustment[4].


  6. Gillard, Michel, et al. "Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: Relationship to anti-convulsant properties." European Journal of Pharmacology664.1(2011]:36-44.
  7. Yang, X., et al. "Brivaracetam augments short-term depression and slows vesicle recycling. " Epilepsia 56.12(2016]:1899-1909.
  8. Nicolas, J. M., et al. "Brivaracetam, a selective high-affinity synaptic vesicle protein 2A[SV2A] ligand with preclinical evidence of high brain permeability and fast onset of action. " Epilepsia 57.2(2016]:201-209.
  9. Vogl, Christian, et al. "The SV2A Ligand Levetiracetam Inhibits Presynaptic Ca2+ Channels Via an Intracellular Pathway."[2012].
  10. Briviact® US Prescribing Information. Brussels, Belgium: UCB, 2016.


Treatment ofTreatment of epilepsy, neuropathic pain and essential tremor.


ChEBI: A non-proteinogenic amino acid derivative that is butanamide in which the pro-S hydrogen at position 2 is replaced by a (4R)-2-oxo-4-propylpyrrolidin-1-yl. Used for treatment of partial onset seizures related to epilepsy.

brivaracetam Preparation Products And Raw materials

Raw materials

Preparation Products

brivaracetam Suppliers

Global( 144)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Nanjing Gold Pharmaceutical Technology Co. Ltd.
025-84209270 15906146951
025-84209270 CHINA 115 55
Beijing Cooperate Pharmaceutical Co.,Ltd.
+86-10-60279497 +86(0)15646567669
+86-10-60279497 CHINA 1817 55
0086-13720134139 CHINA 968 58
Shanghai Jinghao Pharmaceutical Co.,Ltd
+86-21-68900963 CHINA 127 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693 CHINA 22626 55
+86 21 5161 9050/ 5187 7795
+86 21 5161 9052/ 5187 7796 CHINA 24723 60
career henan chemical co
+86-371-86658258 CHINA 30045 58
Hebei Huanhao Biotechnology Co., Ltd.
86-0311-83975816 CHINA 817 58
TianYuan Pharmaceutical CO.,LTD
+86-755-23284190 13684996853
+86-755-23284190 CHINA 305 58
Jinan Shengqi pharmaceutical Co,Ltd
86+18663751872 CHINA 556 58

View Lastest Price from brivaracetam manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2020-05-18 Brivaracetam
US $1.00 / ASSAYS 1ASSAYS 99.99% 100kg Hebei Huanhao Biotechnology Co., Ltd.
2018-07-25 brivaracetam
US $100.00 / KG 100G 98% 200KG career henan chemical co

357336-20-0(brivaracetam)Related Search:

  • brivaracetam
  • (alphaS,4R)-alpha-Ethyl-2-oxo-4-propyl-1-pyrrolidineacetamide
  • UCB-34714
  • 1-PyrrolidineacetaMide, α-ethyl-2-oxo-4-propyl-, (αS,4R)-
  • (S)-2-((R)-2-oxo-4-propylpyrrolidin-1-yl)butanaMide
  • 2(S)-[2-Oxo-4(R)-propylpyrrolidin-1-yl]butyramide
  • (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide
  • API-Anti Epilepsy
  • Briviact
  • 357336-20-0
  • 6305-51-2
  • 3573360-20-0
  • APIs
  • Brain health drug
  • Nootropic
  • API
Copyright 2017 © ChemicalBook. All rights reserved